Composite

Part:BBa_K1795024

Designed by: Joseph L Maniaci   Group: iGEM15_William_and_Mary   (2015-09-17)
Revision as of 07:14, 12 October 2022 by Liu Jiankai (Talk | contribs) (iGEM2022_Nanjing-China Experiment)


KanR Operon under R0010

Provides Kanamycin Resistance to the cell under the Promoter R0010.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


iGEM2022_Nanjing-China Experiment

Homologous recombination device design

Group: Nanjing-China 2022
Author: Jiankai Liu

We believe that there are two modes to improve part. One is to optimize the performance of the existing functions of part, and the other is to expand its application scenarios. Here we chose the latter to implement the improvement of BBa_K1795024.

The existing part BBa_K1795024 provides Kanamycin resistance to the cell under the Promoter R0010. In the absence of LacI protein and CAP protein, this part promotes KanR transcription. In the presence of LacI protein and CAP protein, this part inhibits KanR transcription.

Combined with our own project requirements, we hope to engineer it into a reporter gene of homologous recombination. We kept the KanR coding region and removed its initiation codon so that KanR shares the same initiation codon with BpfA. Then Kanamycin resistance can be used as the basis to judge whether the strain is recombinant that displays silver-binding protein. The recombinant is able to grow on the plate with kanamycin, only if the goal sequence and KanR are recombined to the C-terminal of BpfA successfully.


[edit]
Categories
Parameters
None